Orchestra BioMed Holdings Inc. Market Cap ($327.57 Million)
Market Cap & Net Worth: Orchestra BioMed Holdings Inc. (OBIO)
Orchestra BioMed Holdings Inc. market cap. Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) has a market capitalization of $327.57 Million ($327.57 Million) as of November 9, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14099 globally and #3378 in its home market, demonstrating a -6.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orchestra BioMed Holdings Inc.'s stock price $5.68 by its total outstanding shares 60105049 (60.11 Million). Also see OBIO operating cash flow for how efficiently the company converts equity into cash flow.
Orchestra BioMed Holdings Inc. Market Cap History (2020–2026)
Orchestra BioMed Holdings Inc. market cap history from 2020 to 2026. Data shows change from $769.95 Million to $341.40 Million (-10.53% CAGR). Check today's stock price for Orchestra BioMed Holdings Inc. for real-time trading data and today's change.
Index Memberships
Orchestra BioMed Holdings Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.01% | #373 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #1372 of 3165 |
Weight: Orchestra BioMed Holdings Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Orchestra BioMed Holdings Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orchestra BioMed Holdings Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Orchestra BioMed Holdings Inc. net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.45x
Orchestra BioMed Holdings Inc.'s market cap is 7.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $769.95 Million | $5.70 Million | -$21.36 Million | 135.01x | N/A |
| 2021 | $605.86 Million | $-782.00K | -$23.01 Million | -774.76x | N/A |
| 2022 | $599.85 Million | $3.53 Million | -$33.61 Million | 169.78x | N/A |
| 2023 | $548.76 Million | $2.76 Million | -$49.12 Million | 198.83x | N/A |
| 2024 | $252.44 Million | $2.64 Million | -$61.02 Million | 95.69x | N/A |
| 2025 | $249.44 Million | $33.48 Million | -$52.70 Million | 7.45x | N/A |
Competitor Companies of OBIO by Market Capitalization
Companies near Orchestra BioMed Holdings Inc. in the global market cap rankings as of November 9, 2026. Also see Orchestra BioMed Holdings Inc. total assets for a full breakdown of the balance sheet.
Key companies related to Orchestra BioMed Holdings Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Orchestra BioMed Holdings Inc. (2020–2026)
Market capitalization of Orchestra BioMed Holdings Inc. from 2020 to today. Between 2020 and today, Orchestra BioMed Holdings Inc.'s market cap moved from $769.95 Million to $ 341.40 Million, with a yearly change of -10.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $341.40 Million | +36.87% |
| 2025 | $249.44 Million | -1.19% |
| 2024 | $252.44 Million | -54.00% |
| 2023 | $548.76 Million | -8.52% |
| 2022 | $599.85 Million | -0.99% |
| 2021 | $605.86 Million | -21.31% |
| 2020 | $769.95 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Orchestra BioMed Holdings Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $327.57 Million USD |
| MoneyControl | $327.57 Million USD |
| MarketWatch | $327.57 Million USD |
| marketcap.company | $327.57 Million USD |
| Reuters | $327.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more